Giovanni Melillo, Vice President – Immuno-oncology, Global Medical Affairs AstraZeneca, shared a post on LinkedIn:
“Each year I come to ASCO with a sense of excitement and curiosity. And even after attending for decades, that feeling hasn’t faded.
What continues to make this meeting so special is that there is always something new to learn, a fresh perspective to consider and another reminder of just how quickly oncology continues to evolve. It is also a chance to reconnect with longstanding colleagues and friends, while meeting new voices and new talent helping shape the future of cancer care.
This year, I found myself reflecting on how far we’ve come. Twenty years ago, many of the advances we now discuss as real-world possibilities felt more like distant ambitions. Progress in areas such as KRAS-targeted innovation is a powerful example of that shift – once something we could only really dream about…now a reality with meaningful potential for patients.
It’s moments like these that remind me how fortunate I am to work in oncology. It is an incredibly dynamic field, where scientific ambition, collaboration and innovation can translate into real impact for patients. What makes this work even more meaningful is the opportunity to do it with exceptional colleagues whose dedication and focus on patients drive progress forward every day.
ASCO continues to be a powerful reminder not only of how much progress has been made, but of how much possibility still lies ahead.”
Other articles about ASCO on OncoDaily.
